| Literature DB >> 33372073 |
Meiping Wang1,2, Bo Zhu2, Li Jiang2,3, Ying Wen2,4, Bin Du5, Wen Li2, Guangxu Liu1, Wei Li1, Jing Wen1, Yan He6, Xiuming Xi7.
Abstract
OBJECTIVES: Fluid management is important in ensuring haemodynamic stability in critically ill patients, but can easily lead to fluid overload (FO). However, the optimal fluid balance plot or range for critically ill patients is unknown. This study aimed to explore the dose-response relationship between FO and in-hospital mortality in critically ill patients.Entities:
Keywords: accident & emergency medicine; adult intensive & critical care; general medicine (see internal medicine)
Year: 2020 PMID: 33372073 PMCID: PMC7772328 DOI: 10.1136/bmjopen-2020-039875
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of patients. CCCST, China Critical Care Sepsis Trial; ICU, intensive care unit.
Characteristics and outcomes of patients stratified according to the percentage of maximum FO
| Characteristics | Percentage of maximum FO, L/kg | P value | |||
| All patients (N=3850) | Maximum FO <5% | 5%≤ maximum FO <10% | Maximum FO ≥10% | ||
| Age in years, mean±SD | 61.8±18.1 | 61.0±18.2 | 62.3±18.2 | 62.8±17.9 | 0.023 |
| Sex, male, n (%) | 2501 (65.0) | 1201 (63.8) | 693 (67.3) | 607 (64.7) | 0.170 |
| Illness severity scores, median (IQR) | |||||
| APACHE II | 17.0 (12.0–23.0) | 16.0 (11.0–22.0) | 18.0 (12.0–23.0) | 20.0 (14.0–26.0) | <0.001 |
| SOFA | 8.5 (5.5–11.3) | 7.0 (4.0–10.0) | 8.5 (5.0–11.3) | 10.0 (7.0–13.0) | <0.001 |
| Main diagnosis, n (%) | <0.001 | ||||
| Sepsis | 1258 (32.7) | 510 (27.1) | 359 (34.9) | 389 (41.5) | |
| Respiratory disease | 707 (18.4) | 376 (20.0) | 195 (18.9) | 136 (14.5) | |
| Cardiovascular disease | 299 (7.8) | 227 (12.1) | 48 (4.7) | 24 (2.6) | |
| Neurological disease | 239 (6.2) | 136 (7.2) | 72 (7.0) | 31 (3.3) | |
| Trauma | 240 (6.2) | 98 (5.2) | 66 (6.4) | 76 (8.1) | |
| Postoperative care | 558 (14.5) | 269 (14.3) | 150 (14.6) | 139 (14.8) | |
| Gastrointestinal disease | 300 (7.8) | 120 (6.4) | 81 (7.9) | 99 (10.6) | |
| Others | 249 (6.6) | 146 (7.8) | 59 (5.7) | 44 (4.6) | |
| Comorbidities, n (%) | |||||
| Respiratory disease | 290 (7.5) | 126 (6.7) | 88 (8.5) | 76 (8.1) | 0.146 |
| Cardiovascular disease | 663 (17.2) | 334 (17.7) | 171 (16.6) | 158 (16.8) | 0.692 |
| Hypertension | 1321 (34.3) | 680 (36.1) | 333 (32.3) | 308 (32.8) | 0.065 |
| Diabetes mellitus | 716 (18.6) | 345 (18.3) | 204 (19.8) | 167 (17.8) | 0.479 |
| Chronic renal dysfunction | 245 (6.4) | 129 (6.9) | 59 (5.7) | 57 (6.1) | 0.452 |
| Malignant tumour | 373 (9.7) | 174 (9.2) | 105 (10.2) | 94 (10.0) | 0.656 |
| Cirrhosis | 106 (2.8) | 31 (1.6) | 35 (3.4) | 40 (4.3) | <0.001 |
| None | 1145 (29.7) | 577 (30.7) | 305 (29.6) | 263 (28.0) | 0.356 |
| Mechanical ventilation, n (%) | 2766 (71.8) | 1210 (64.3) | 768 (74.6) | 788 (84.0) | <0.001 |
| Renal replacement therapy, n (%) | 716 (18.6) | 295 (15.7) | 186 (18.1) | 235 (25.1) | <0.001 |
| Vasopressors, n (%) | 1820 (47.3) | 791 (42.0) | 517 (50.2) | 512 (54.6) | <0.001 |
| Mortality, n (%) | |||||
| In-hospital | 929 (24.1) | 330 (17.5) | 266 (25.8) | 333 (35.5) | <0.001 |
| In-ICU | 812 (21.1) | 293 (15.6) | 223 (21.7) | 296 (31.6) | <0.001 |
| Length of stay, days (IQR) | |||||
| ICU | 8.0 (4.0–15.0) | 6.5 (4.0–12.5) | 8.0 (4.5–15.0) | 10.0 (7.0–17.0) | <0.001 |
| Hospital | 19.0 (11.0–28.0) | 18.0 (11.0–27.0) | 19.0 (12.0–29.0) | 19.0 (13.0–30.0) | <0.001 |
FO, fluid overload; ICU, intensive care unit; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment.
Results of the Cox proportional hazard regression analysis of the risk of in-hospital mortality
| Maximum FO as a continuous variable* | Maximum FO as a nominal variable | ||||
| HR (95% CI) | P value | Maximum FO <5% (n=1475) | 5%≤ maximum FO <10% (n=773) | Maximum FO ≥10% (n=596) | |
| Model 1 | 1.06 (1.04 to 1.08) | <0.001 | 1.000 | 1.38 (1.14 to 1.62) | 2.11 (1.86 to 2.42) |
| Model 2 | 1.05 (1.03 to 1.07) | <0.001 | 1.000 | 1.36 (1.15 to 1.61) | 1.81 (1.56 to 2.11) |
| Model 3 | 1.04 (1.01 to 1.06) | <0.001 | 1.000 | 1.30 (1.07 to 1.48) | 1.63 (1.37 to 1.93) |
| Model 4 | 1.04 (1.03 to 1.05) | <0.001 | 1.000 | 1.27 (1.10 to 1.52) | 1.44 (1.25 to 1.67) |
Model 1: crude HR.
Model 2: adjusted for age, sex and APACHE II score.
Model 3: additionally adjusted for main diagnosis and comorbidities.
Model 4: additionally adjusted for time of maximum fluid overload, mechanical ventilation, renal replacement therapy and use of vasopressors.
*HR was examined per 1% (L/kg) increase in maximum FO.
APACHE II, Acute Physiology and Chronic Health Evaluation II; FO, fluid overload.
Figure 2Distribution of the maximum fluid overload in all patients.
Figure 3Adjusted OR between maximum fluid overload and in-hospital mortality (A) for all and (B) following propensity score matching. The black line indicates the adjusted OR, and the red lines indicate the 95% CI bands. The vertical grey dashed lines indicate 5% and 10% L/kg of the maximum fluid overload. The reference for the maximum fluid overload is 0%. Data were fitted using a multivariable logistic regression model with a restricted cubic spline with four knots (5th, 35th, 65th and 95th percentiles) for maximum fluid overload which was adjusted for potential confounders (model 4). Due to the small sample size, the lowest 5% and highest 5% of participants are not shown in the figures.
Figure 4Adjusted OR between maximum fluid overload and in-hospital mortality in patients with (A) or without (B) shock. The black line indicates the adjusted OR, and the red lines indicate the 95% CI bands. The vertical grey dashed lines indicate 5% and 10% L/kg of the maximum fluid overload. The reference for the maximum fluid overload is 0%. Data were fitted using a multivariable logistic regression model with a restricted cubic spline with four knots (5th, 35th, 65th and 95th percentiles) for maximum fluid overload which was adjusted for potential confounders (model 4). Due to the small sample size, the lowest 5% and highest 5% of participants are not shown in the figures.